Migraine and Its Association with Hyperactivity of Cell Membranes in the Course of Latent Magnesium Deficiency-Preliminary Study of the Importance of the Latent Tetany Presence in the Migraine Pathogenesis.

Plain-language guide to PMID 34444861 (2021): clinical trial of Vitamin D, K2, Magnesium and Zinc in 35 patients, migraine.

Key Facts

PMID: 34444861
Journal: Nutrients
Year: 2021
Study type: Clinical Trial
Authors: Cegielska J et al. (6 authors)
DOI: 10.3390/nu13082701

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of migraine, published as a clinical trial.

The aim of the study was to evaluate the influence of latent magnesium deficiency assessed with the electrophysiological tetany test on the course of migraine.

Why It Was Studied

So far, there is no consistent and convincing theory explaining the pathogenesis of migraines.

Vascular disorders, the effect of oxidative stress on neurons, and the contribution of magnesium-calcium deficiencies in triggering cortical depression and abnormal glutaminergic neurotransmission are taken into account.

Who Took Part

According to the abstract, 35 patients were involved.

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

What Was Measured

All patients and controls after full general and neurological examination were subjected to a standard electrophysiological ischemic tetany test.

Moreover, the level of magnesium in blood serum was tested and was in the normal range in all patients.

The subject headings attached to it are Case-Control Studies, Causality, Cell Membrane, Electromyography, Magnesium, Magnesium Deficiency and Migraine Disorders.

Author keywords: CSD, NMDA receptor, electrophysiological tetany test with ischemia and hyperventilation, neuromuscular hyperactivity, spasmophilia and tetany.

What This Means in Plain Language

This is a clinical trial of Vitamin D, K2, Magnesium and Zinc in 35 patients in people with migraine.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2021 (Nutrients), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Migraine research.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.